Bio-Works Technologies AB (BIOWKS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bio-Works Technologies AB (BIOWKS) has a cash flow conversion efficiency ratio of -0.236x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.09 Million ≈ $-762.57K USD) by net assets (Skr30.04 Million ≈ $3.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bio-Works Technologies AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Bio-Works Technologies AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bio-Works Technologies AB total liabilities for a breakdown of total debt and financial obligations.
Bio-Works Technologies AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-Works Technologies AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHL Telemedicine Ltd American Depositary Shares
NASDAQ:SHLT
|
-0.004x |
|
Jentayu Sustainables Bhd
KLSE:5673
|
-0.071x |
|
Mohenz.Co.Ltd
KQ:006920
|
0.017x |
|
Naos Small Cap Opportunities Company Ltd
AU:NSC
|
0.063x |
|
Wellbiotec Co. Ltd.
KO:010600
|
-0.033x |
|
Camino Minerals Corporation
V:COR
|
-0.025x |
|
TransAct Technologies Incorporated
NASDAQ:TACT
|
0.114x |
|
Wintec Co. Ltd
KQ:320000
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Bio-Works Technologies AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of Bio-Works Technologies AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Bio-Works Technologies AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr44.58 Million ≈ $4.80 Million |
Skr-43.17 Million ≈ $-4.65 Million |
-0.968x | +27.73% |
| 2023-12-31 | Skr44.03 Million ≈ $4.74 Million |
Skr-58.99 Million ≈ $-6.35 Million |
-1.340x | -127.40% |
| 2022-12-31 | Skr67.69 Million ≈ $7.28 Million |
Skr-39.88 Million ≈ $-4.29 Million |
-0.589x | -378.17% |
| 2021-12-31 | Skr108.51 Million ≈ $11.68 Million |
Skr-13.37 Million ≈ $-1.44 Million |
-0.123x | +89.36% |
| 2020-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-43.36 Million ≈ $-4.67 Million |
-1.158x | -137.44% |
| 2019-12-31 | Skr82.13 Million ≈ $8.84 Million |
Skr-40.04 Million ≈ $-4.31 Million |
-0.488x | +13.37% |
| 2018-12-31 | Skr61.64 Million ≈ $6.63 Million |
Skr-34.69 Million ≈ $-3.73 Million |
-0.563x | -163.23% |
| 2017-12-31 | Skr99.32 Million ≈ $10.69 Million |
Skr-21.23 Million ≈ $-2.28 Million |
-0.214x | +65.04% |
| 2016-12-31 | Skr23.64 Million ≈ $2.54 Million |
Skr-14.46 Million ≈ $-1.56 Million |
-0.612x | -4.42% |
| 2015-12-31 | Skr22.41 Million ≈ $2.41 Million |
Skr-13.12 Million ≈ $-1.41 Million |
-0.586x | -- |
About Bio-Works Technologies AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chr… Read more